Rentschler Biopharma

At Rentschler Biopharma, we are a leading contract development and manufacturing organization (CDMO) focused exclusively on our clients’ projects. We provide process development and manufacturing services for biopharmaceuticals, complemented by consulting, project management and regulatory support.

Our reputation is built on decades of experience and a commitment to quality, making us a trusted solutions partner for biotechnology and pharmaceutical companies worldwide. A robust quality management system, a well-established operational excellence philosophy and advanced technologies help ensure product quality and productivity at every stage of development and manufacturing.

As a family-owned company with approximately 1,700 employees, we are headquartered in Laupheim, Germany, and operate a state-of-the-art manufacturing site in Milford, Massachusetts, USA. Over the years, we have supported a wide range of therapeutic modalities through development and manufacturing, regularly contributing to biopharmaceutical products that achieve regulatory approval. In 2023 alone, we contributed to nearly 25% of all FDA-approved biologics.

Our commitment extends beyond scientific and operational excellence. In 2024, we joined the United Nations Global Compact, reinforcing our focus on sustainability and responsible business practices.

Interested in joining Rentschler Biopharma? Explore current career opportunities here.

From Vision to Commercialization: How Rentschler Biopharma Partners for Client Success
On Now
From Vision to Commercialization: How Rentschler Biopharma Partners for Client Success
On Now
Tech Transfer Powered by Dual-Site Precision
On Now
Reliability you can trust - Our Rentschler Biopharma manufacturing site in Milford, MA, USA

OUR EXPERTISE
Your World-Class BioPharmaceutical CDMO
50+
Years of exceptional biotechnology expertise and experience from concept to market
180
Longstanding experience in biotherapeutics, supported by full-service solution
100+
Successful submissions for clinical trials
180+
International clients serves since 1997
50%+
Biotherapeutics are complex proteins, including advanced antibody formats and recombinant enzymes
Top 20
Most of the Big Pharma companies are our clients
NEWS
Of the 38 companies receiving incentives, 31 will expand outside of Boston and Cambridge. Still, Boston and Cambridge are each expected to gain over 200 jobs. Tax incentive award recipients include AstraZeneca, Bristol Myers Squibb and Insulet.
With the Thanksgiving season upon us, there are many reasons for biopharma and life sciences companies to say thanks, including for new leaders.
This week’s Movers & Shakers include Arvinas, Inspire and Cambridge Isotope Laboratories all announcing new VP roles, and several others tap new C-suite executives.
It’s not unusual for biopharma companies to end the year with a restructuring that includes job cuts. Here are some of these companies.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
CureVac NV is downsizing its European mRNA production network due to decreased demand for vaccines after the first wave of vaccinations.
August has been busy with a flurry of life sciences expansion announcements, particularly in the United States and Canada. Here’s a look at a few companies increasing their presence in the two countries.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
IN THE PRESS
JOBS